These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12227060)

  • 41. Another ingredient added to HER2 mix.
    Titus K
    CAP Today; 1999 Nov; 13(11):1, 20-4, 26 passim. PubMed ID: 10724678
    [No Abstract]   [Full Text] [Related]  

  • 42. HER2 in prostate cancer--a viable target or innocent bystander?
    Scher HI
    J Natl Cancer Inst; 2000 Dec; 92(23):1866-8. PubMed ID: 11106669
    [No Abstract]   [Full Text] [Related]  

  • 43. HER2 testing: the patent "genee" is out of the bottle.
    Goldman B
    CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
    [No Abstract]   [Full Text] [Related]  

  • 44. Experts debate value of HER2 testing methods.
    Nelson NJ
    J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369
    [No Abstract]   [Full Text] [Related]  

  • 45. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.
    Kumar-Sinha C; Ignatoski KW; Lippman ME; Ethier SP; Chinnaiyan AM
    Cancer Res; 2003 Jan; 63(1):132-9. PubMed ID: 12517789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted cancer therapies attempt to hit the bull's-eye.
    Miller M
    J Natl Cancer Inst; 2000 Dec; 92(23):1878-9. PubMed ID: 11106678
    [No Abstract]   [Full Text] [Related]  

  • 47. As metastasis yields its biological secrets, researchers hope to apply findings.
    Benowitz S
    J Natl Cancer Inst; 2008 Aug; 100(15):1054-7. PubMed ID: 18664646
    [No Abstract]   [Full Text] [Related]  

  • 48. Oleic acid suppresses overexpression of ERBB2 oncogene.
    Nelson R
    Lancet Oncol; 2005 Feb; 6(2):69. PubMed ID: 15704291
    [No Abstract]   [Full Text] [Related]  

  • 49. Not quite pharmacogenomics.
    Haseltine WA
    Nat Biotechnol; 1998 Dec; 16(13):1295. PubMed ID: 9853593
    [No Abstract]   [Full Text] [Related]  

  • 50. Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
    Hirte HW; Hotte SJ
    J Clin Oncol; 2008 Jul; 26(20):3301-2. PubMed ID: 18490647
    [No Abstract]   [Full Text] [Related]  

  • 51. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.
    Stern DF
    Breast Cancer Res; 2000; 2(3):176-83. PubMed ID: 11250707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2 and proliferation of wound-induced breast carcinoma.
    Tez M; Göçmen E; Ozçelik T
    Lancet; 2003 Nov; 362(9394):1503; author reply 1503. PubMed ID: 14602459
    [No Abstract]   [Full Text] [Related]  

  • 53. The "other" signaling of trastuzumab: antibodies are immunocompetent drugs.
    Gianni L
    J Clin Oncol; 2008 Apr; 26(11):1778-80. PubMed ID: 18347004
    [No Abstract]   [Full Text] [Related]  

  • 54. Interaction of antibodies with ErbB receptor extracellular regions.
    Schmitz KR; Ferguson KM
    Exp Cell Res; 2009 Feb; 315(4):659-70. PubMed ID: 18992239
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ASCO 2011: broadening the horizons of cancer research.
    Crane K
    J Natl Cancer Inst; 2011 Jul; 103(13):999-1001. PubMed ID: 21693729
    [No Abstract]   [Full Text] [Related]  

  • 56. New blood test can detect genes that drive cancer and help to determine best treatment.
    Kmietowicz Z
    BMJ; 2013 May; 346():f2825. PubMed ID: 23635918
    [No Abstract]   [Full Text] [Related]  

  • 57. Natural medicine: a 'new frontier' in oncology?
    Marchetti P
    Ann Oncol; 2005 Mar; 16(3):339-40. PubMed ID: 15722460
    [No Abstract]   [Full Text] [Related]  

  • 58. Trastuzumab.
    Pittsley K
    Clin J Oncol Nurs; 2000; 4(5):235-6. PubMed ID: 11111456
    [No Abstract]   [Full Text] [Related]  

  • 59. HER2 testing.
    Horten B; Da Silva M; Thompson J
    CAP Today; 2001 Jan; 15(1):8-9. PubMed ID: 11317560
    [No Abstract]   [Full Text] [Related]  

  • 60. Breast cancer: Should we assess HER2 status by Oncotype DX?
    Ignatiadis M; Sotiriou C
    Nat Rev Clin Oncol; 2011 Dec; 9(1):12-4. PubMed ID: 22143144
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.